Abstract
As many patients with underlying psychiatric disorders may be infected with COVID-19, and COVID-19-affected subjects may frequently experience a new onset of psychiatric manifestations, concomitant use of psychotropic medications and COVID-19 therapies is expected to be highly likely and raises concerns of clinically relevant drug interactions. In this setting, four major mechanisms responsible for drug interactions involving psychotropic agents and COVID-19 therapies may be identified: (1) pharmacokinetic drug-drug interactions mainly acting on cytochrome P450; (2) pharmacodynamic drug-drug interactions resulting in additive or synergistic toxicity; (3) drug-disease interactions according to stage and severity of the disease; and (4) pharmacogenetic issues associated with polymorphisms of cytochrome P450 isoenzymes. In this review, we summarise the available literature on relevant drug interactions between psychotropic agents and COVID-19 therapies, providing practical clinical recommendations and potential management strategies according to severity of illness and clinical scenario.
【초록키워드】 COVID-19, therapy, severity, polymorphism, Toxicity, Polymorphisms, management, Patient, Manifestations, Psychiatric disorders, mechanism, Therapies, drug-drug interaction, pharmacokinetic, Drug interactions, Interaction, drug interaction, cytochrome P450, severity of illness, psychiatric disorder, psychotropic agents, Psychiatric, subject, Stage, psychotropic medications, concomitant use, P450, recommendation, Psychotropic medication, synergistic, raise, responsible, resulting, clinically, expected, acting, infected with COVID-19, pharmacogenetic, psychotropic agent, 【제목키워드】 drug, COVID-19 therapy, agent, Significant, Psychotropic,